BCAS2 Antibody | 5627

BCAS2 Antibody | 5627 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: BCAS2 antibody was raised against a 14 amino acid synthetic peptide near the carboxy terminus of human BCAS2.
The immunogen is located within the last 50 amino acids of BCAS2.

Research Area: Cancer, Cell Cycle

Tested Application: E, WB, IHC-P, IF

Application: BCAS2 antibody can be used for detection of BCAS2 by Western blot at 0.5 - 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1219 - MCF7 Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: BCAS2 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: BCAS2 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: BCAS2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: BCAS2 Antibody: DAM1, SPF27, Snt309, DAM1, Pre-mRNA-splicing factor SPF27, Breast carcinoma-amplified sequence 2

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: BCAS2 Antibody: BCAS2 was identified through differential display analysis as an mRNA species that was overexpressed in MCF7 and BT-20 breast cancer cell lines. The chromosomal region containing this gene, 1p13.3021, is amplified in these cells lines. BCAS2 is a transcriptional cofactor that enhances estrogen receptor-mediated gene expression, and directly interacts with the tumor suppressor p53 to reduce p53 transcriptional activity by reducing p53 protein level in the absence of DNA damage. Deprivation of BCAS2 through RNA inhibition induces apoptosis in p53-wild type cells, but causes G2-M arrest in p53-null or -mutant cells; this effect was reversed with the expression of ectopic BCAS2. BCAS2 may thus be potentially useful as a therapeutic target in the treatment of cancer.